DTEBOP2: Bayesian Optimal Phase II Randomized Clinical Trial Design withDelayed Outcomes
Implements a Bayesian Optimal Phase II design (DTE-BOP2) for trials with delayed treatment effects, particularly relevant to immunotherapy studies where treatment benefits may emerge after a delay. The method builds upon the BOP2 framework and incorporates uncertainty in the delay timepoint through a truncated gamma prior, informed by expert knowledge or default settings. Supports two-arm trial designs with functionality for sample size determination, interim and final analyses, and comprehensive simulation under various delay and design scenarios. Ensures rigorous type I and II error control while improving trial efficiency and power when the delay effect is present. A manuscript describing the methodology is under development and will be formally referenced upon publication.
| Version: | 1.0.3 |
| Depends: | R (≥ 3.5.0) |
| Imports: | truncdist,doParallel,foreach, parallel,invgamma |
| Suggests: | knitr,rmarkdown,survRM2adapt,ggplot2,reconstructKM,survival,survminer |
| Published: | 2025-05-09 |
| DOI: | 10.32614/CRAN.package.DTEBOP2 |
| Author: | Zhongheng Cai [aut, cre], Haitao Pan [aut] |
| Maintainer: | Zhongheng Cai <zhonghengcai123 at gmail.com> |
| License: | GPL-3 |
| NeedsCompilation: | no |
| CRAN checks: | DTEBOP2 results |
Documentation:
Downloads:
Linking:
Please use the canonical formhttps://CRAN.R-project.org/package=DTEBOP2to link to this page.